Based on Sandoz Group Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.06 billion and a GAAP net loss of $150 mil ...

Novo Nordisk, the Danish pharma company behind Ozempic and Wegovy, made one very dumb decision a few years ago that will ...

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sandoz Group Ltd with a $51.82 average price target.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...